Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Olodaterol

(Striverdi Respimat®)

Striverdi Respimat®

Drug updated on 11/1/2024

Dosage FormInhalation spray (oral: 2.5 mcg)
Drug ClassLong-acting beta2-adrenergic agonist (LABA)
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
  • Olodaterol/tiotropium demonstrated a lower moderate or severe exacerbation rate of 38.3% at 52 weeks compared to other long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) and LABA/ICS (inhaled corticosteroid) combinations, such as formoterol/budesonide (41.0%), indacaterol/glycopyrronium (42.6%), and vilanterol/umeclidinium (53.0%).
  • In lung function outcomes, vilanterol/umeclidinium showed the highest efficacy in trough FEV(1) change from baseline, while olodaterol/tiotropium showed similar efficacy to other LABA/LAMA combinations, with a gradual decline in trough FEV(1) over 24 weeks observed across all combinations except vilanterol/umeclidinium (0.029–0.041 L decrease).
  • Across various LABA/LAMA FDCs (fixed-dose combinations), similar safety outcomes were observed for mortality, serious adverse events (SAEs), and withdrawal due to adverse events, with no significant safety differences reported compared to placebo.
  • For cardiovascular safety, tiotropium/olodaterol (5/5 µg) demonstrated no significant increase in risks for arrhythmia, heart failure, myocardial infarction, or stroke compared to individual components, indicating an acceptable safety profile for cardiovascular outcomes.
  • Among maintenance-naive patients with COPD (chronic obstructive pulmonary disease), tiotropium/olodaterol significantly improved lung function (measured by trough FEV₁), health status (SGRQ (St. George's Respiratory Questionnaire) score), and dyspnea severity (TDI (Transition Dyspnoea Index) score) compared to tiotropium alone, with no reported compromise in safety outcomes.